Potential use of olanzapine in treatment of substance dependence disorders [1]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 4, 2003, Pages 413-415

  Sattar, S Pirzada ^a,b   Grant, Kathleen ^a,b   Bhatia, Subhash ^a,b   Petty, Frederick ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; DIPHENHYDRAMINE; GABAPENTIN; HALOPERIDOL; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; TRAZODONE; VALPROIC ACID;

ADULT; ALCOHOLISM; CASE REPORT; CLINICAL FEATURE; COCAINE DEPENDENCE; CONSTIPATION; DETOXIFICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; FATIGUE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO;

ALCOHOLISM; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COCAINE-RELATED DISORDERS; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 0041632389     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000085417.08426.54     Document Type: Letter

References (10)

1. Bowers MB, Mazure CM, Nelson JC, et al. Pyschogenic drug use and neuroleptic response. Schizophr Bull. 1990;16(1):81-85.
2. Wilkins JN. Pharmacologic treatment of substance abusing schizophrenia patients. Schizophr Bull. 1997;23(2):215-228.
3. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 1995;119(1):124-126.
4. Sattar SP, Ucci B, Grant K, et al. Quetiapine as an adjunct in a substance abusing veteran with PTSD. Ann Pharmacother. 2002;36(12):1875-1878.
5. Khantzian E. The self-medication hypothesis of addictive disorders. Am J Psychiatry. 1985;142:1259-1264.
6. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment of patients with schizophrenia and substance abuse. J Subst Abuse Treat. 2001;21(4):217-221.
7. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000;32(suppl i-iv):1-112.
8. Green AI, Zimmet SV, Strous RD, et al. Clozapine for co-morbid substance use disorder and schizophrenia: do patients with schizophrenia have a higher reward deficiency syndrome that can be ameliorated by clozapine. Harv Rev Psychiatry. 1999;(4),6(6):287-296.
9. Physicians Desk Reference. Medical Economics Thomas Healthcare. Montvale, NJ; 2002:1973-1978.
10. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull. 1997;33(1):177-181.